Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Iovance Biotherapeutics (IOVA) Net Margin (2023 - 2025)

Iovance Biotherapeutics has reported Net Margin over the past 4 years, most recently at 82.92% for Q4 2025.

  • Quarterly results put Net Margin at 82.92% for Q4 2025, up 2370.0% from a year ago — trailing twelve months through Dec 2025 was 148.41% (up 7844.0% YoY), and the annual figure for FY2025 was 148.38%, up 7846.0%.
  • Net Margin for Q4 2025 was 82.92% at Iovance Biotherapeutics, up from 135.28% in the prior quarter.
  • Over the last five years, Net Margin for IOVA hit a ceiling of 82.92% in Q4 2025 and a floor of 44759.66% in Q2 2023.
  • Median Net Margin over the past 3 years was 235.59% (2025), compared with a mean of 10014.43%.
  • Biggest five-year swings in Net Margin: skyrocketed 4444750bps in 2024 and later soared 739bps in 2025.
  • Iovance Biotherapeutics' Net Margin stood at 24140.87% in 2023, then skyrocketed by 100bps to 106.62% in 2024, then grew by 22bps to 82.92% in 2025.
  • The last three reported values for Net Margin were 82.92% (Q4 2025), 135.28% (Q3 2025), and 186.27% (Q2 2025) per Business Quant data.